Journal of Yeungnam Medical Science

Yeungnam University College of Medicine, Yeungnam University Institute Medical Science (영남대 의대 학술지 편집위원회)
권호 표지
DOI QR코드

DOI QR Code

Successful engraftment after infusion of multiple low doses of CD34+ cells from a poorly matched sibling donor in a patient with severe aplastic anemia

  • Kum, Chang Dae (Department of Pediatrics, Ajou University School of Medicine) ;
  • Lee, Mi Jin (Department of Pediatrics, Ajou University School of Medicine) ;
  • Park, Jun Eun (Department of Pediatrics, Ajou University School of Medicine)
  • Received : 2018.09.26
  • Accepted : 2018.10.19
  • Published : 2019.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

The dose of CD34+ cells is known to influence the outcome of allogeneic peripheral blood stem cell (PBSC) and/or T-cell-depleted transplantation. A previous study proposed that $2{\times}10^6\;CD34+\;cells/kg$ is the ideal minimum dose for allogeneic transplantation, although lower doses did not preclude successful therapy. In the case we present here, CD34+ cells were collected from a matched sibling donor on the day of allogeneic hematopoietic stem cell transplantation; however, the number of cells was not sufficient for transplantation. Consequently, PBSCs were collected three additional times and were infused along with cord blood cells from the donor that were cryopreserved at birth. The cumulative dose of total nuclear cells and CD34+ cells was $15.9{\times}10^8\;cells/kg$ and $0.95{\times}10^6\;cells/kg$, respectively. White blood cells from this patient were engrafted on day 12. In summary, we report successful engraftment after infusion of multiple low doses of CD34+ cells in a patient with severe aplastic anemia.

Keywords

References

  1. Peinemann F, Grouven U, Kroger N, Pittler M, Zschorlich B, Lange S. Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review. Haematologica 2009;94:1732-42. https://doi.org/10.3324/haematol.2009.007583
  2. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813-26. https://doi.org/10.1056/NEJMra052638
  3. Bacigalupo A. Guidelines for the treatment of severe aplastic anemia. Working Party on Severe Aplastic Anemia (WPSAA) of the European Group of Bone Marrow Transplantation(EBMT). Haematologica 1994;79:438-44.
  4. Young NS, Barrett AJ. The treatment of severe acquired aplastic anemia. Blood 1995;85:3367-77. https://doi.org/10.1182/blood.V85.12.3367.bloodjournal85123367
  5. Charbonnier A, Sainty D, Faucher C, Arnoulet C, Chabannon C, Blaise D. Immune reconstitution after blood cell transplantation. Hematol Cell Ther 1997;39:261-4. https://doi.org/10.1007/s00282-997-0261-7
  6. Bittencourt H, Rocha V, Chevret S, Socie G, Esperou H, Devergie A, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002;99:2726-33. https://doi.org/10.1182/blood.V99.8.2726
  7. Singhal S, Powles R, Treleaven J, Kulkarni S, Sirohi B, Horton C, et al. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000;26:489-96. https://doi.org/10.1038/sj.bmt.1702542
  8. Bacigalupo A. How I treat acquired aplastic anemia. Blood 2017;129:1428-36. https://doi.org/10.1182/blood-2016-08-693481
  9. Barone A, Lucarelli A, Onofrillo D, Verzegnassi F, Bonanomi S, Cesaro S, et al. Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP). Blood Cells Mol Dis 2015;55:40-7. https://doi.org/10.1016/j.bcmd.2015.03.007
  10. Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 2016;172:187-207. https://doi.org/10.1111/bjh.13853
  11. Islam MS, Anoop P, Datta-Nemdharry P, Sage D, Gordon-Smith EC, Turner D, et al. Implications of CD34+ cell dose on clinical and haematological outcome of allo-SCT for acquired aplastic anaemia. Bone Marrow Transplant 2010;45:886-94. https://doi.org/10.1038/bmt.2009.267
  12. Perez-Simon JA, Caballero MD, Corral M, Nieto MJ, Orfao A, Vazquez L, et al. Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion 1998;38:385-91. https://doi.org/10.1046/j.1537-2995.1998.38498257378.x
  13. Perez-Simon JA, Diez-Campelo M, Martino R, Sureda A, Caballero D, Canizo C, et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood 2003;102:1108-13. https://doi.org/10.1182/blood-2002-11-3503
  14. de la Rubia J, Cantero S, Sanz GF, Remigia MJ, Monteagudo E, Moscardo F, et al. Transplantation of CD34+ selected peripheral blood to HLA-identical sibling patients with aplastic anaemia: results from a single institution. Bone Marrow Transplant 2005;36:325-9. https://doi.org/10.1038/sj.bmt.1705067
  15. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007;21:1733-8. https://doi.org/10.1038/sj.leu.2404777